Immutep Limited (ASX:IMM)

Market Cap	48.63M -87.5%
Revenue (ttm)	19.93M +295.2%
Net Income	-79.30M
EPS	-0.05
Shares Out	1.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,232,785
Open	0.0340
Previous Close	0.0340
Day's Range	0.0320 - 0.0340
52-Week Range	0.0280 - 0.4700
Beta	2.20
Analysts	Buy
Price Target	0.11 (+233.33%)
Est. Earnings	Oct 11, 2026

About Immutep

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 31
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IMM

Financial Performance

In fiscal year 2026, Immutep's revenue was 19.93 million, an increase of 295.22% compared to the previous year's 5.04 million. Losses were -79.30 million, 29.1% more than in 2025.

Analyst Summary

According to 4 analysts, the average rating for IMM stock is "Buy." The 12-month stock price target is $0.11, which is an increase of 233.33% from the latest price.

Price Target

$0.11

(233.33% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error